

2021/22 Month 9 Financial Performance

Author: Tarun Basra - Assistant Director of Financial Performance

Sponsor: Lorraine Hooper – Chief Financial Officer
Trust Board paper I

Purpose of Report:

This paper is for:	Description	Select (X)
Decision	To formally receive a report and approve its recommendations OR a particular course of action	
Discussion	To discuss, in depth, a report noting its implications without formally approving a recommendation or action	X
Assurance	To assure the Board that systems and processes are in place, or to advise a gap along with treatment plan	
Noting	For noting without the need for discussion	

Previous Consideration:

Meeting	Date	Please clarify the purpose of the paper to that meeting using the categories above
Executive Board (specify which)	EFPB 25.1.22	
FRB		
FIC	27.1.22	
Trust Board		

Executive Summary

Context:

This paper updates the Trust Board on the financial performance of the Trust at Month 9 of 2021/22.

Questions:

1. What is the financial performance for the period ending 31st December 2021?

The Trust has reported a Month 9 deficit of £1.9m. This is a £12k adverse variance to forecast. The year to date surplus at Month 9 is £9.2m.

2. What are the main issues to note in the Month 1-9 financial performance?

- Headroom expenditure in Month 9 was £1.8m. Matching system income has not been drawn down due to the surplus year to date Trust position
- The Trust's full year forecast is currently at breakeven after adjusting for the return of £9m of headroom income to the LLR System

Input Sought:

The Trust Board is asked to:

- **Note** the Month 9 (2021/22) reported financial position

For Reference:

This report relates to the following UHL quality and supporting priorities

1. Quality priorities

Safe, surgery and procedures
Safely and timely discharge
Improved Cancer pathways
Streamlined emergency care
Better care pathways
Ward accreditation

Not applicable
Not applicable
Not applicable
Not applicable
Not applicable
Not applicable

2. Supporting priorities

People strategy implementation
Estate investment and reconfiguration
e-Hospital
More embedded research
Better corporate services
Quality strategy development

Not applicable
Not applicable
Not applicable
Not applicable
Not applicable
Not applicable

3. Equality Impact Assessment and Patient and Public Involvement considerations

- What was the outcome of your Equality Impact Assessment (EIA)? **Not applicable**
- Briefly describe the Patient and Public Involvement (PPI) activities undertaken in relation to this report, or confirm that none were required. **None required**
- How did the outcome of the EIA influence your Patient and Public Involvement? **Not applicable**
- If an EIA was not carried out, what was the rationale for this decision? **Not applicable**

4. Risk and Assurance

Risk Reference:

Does this paper reference a risk event?	Select (X)	Risk Description:
Strategic: Does this link to a <i>Principal Risk</i> on the BAF?	X	Principal Risk 4 – Financial Sustainability
Organisational: Does this link to an <i>Operational/Corporate Risk</i> on Datix Register		
New Risk identified in paper: What <i>type</i> and <i>description</i> ?		
None		

- Scheduled date for the **next paper** on this topic: March 2022
- Executive Summaries should not exceed **5 sides** My paper does/~~does not~~ comply



Financial Performance Report

December 2021




One team shared values



Executive Summary

- The Trust has reported a month 9 deficit of £1.9m. This is a £12k adverse variance to forecast. The year to date surplus at month 9 is £9.2m. (Page 10 breaks this down by category of expenditure).
- Headroom expenditure in month 9 was £1.8m. Matching System income has not been drawn down due to the surplus year to date Trust position.
- The Trust's full year forecast is currently at breakeven after adjusting for the return of £9m of headroom income to the LLR System.
- The forecast includes £21.2m of System headroom income as follows:
 - £4.5m winter spend
 - £9m elective recovery spend
 - £2.5m in month 12 relating to UHL 2019/20 recurrent impact of accounts restatement
 - £1.6m relating to overseas nurse recruitment
 - £1.7m marginal cost
 - £1.9m winter resilience
- An allowance of £6.1m is included in the forecast relating to Trust wide non-recurrent invest to save scheme proposals.
- The forecast assumes £3m additional income in month 12 for costs relating to Nightingale Surge Hub.
- The Trust has reported a risk adjusted year to date CIP cash releasing position of £12.8m against a £9.4m CIP target. (Page 11 details CIP delivery).
- The Trust maintained a strong cash position at the end of December of £96.6m.

Key Highlights



NHSE&I issued guidance that the Trust should not accrue or forecast the impact of the pay award prior to month 6

CMG – Worked WTE - Revised Month 9 Workforce Actuals/Forecast

	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Forecast	Forecast	Forecast
	Apr-21	May-21	Jun-21	Jul-21	Aug-21	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22
Total - Worked WTEs												
Substantive	14,178	14,106	14,120	14,070	14,131	14,056	14,126	14,162	14,286	14,385	14,472	14,490
Bank	778	759	710	765	783	832	894	893	936	958	952	990
Agency	371	305	290	301	321	305	331	347	385	411	411	411
Total	15,327	15,169	15,120	15,136	15,235	15,193	15,352	15,402	15,608	15,754	15,835	15,891
Budgeted Posts	15,850	15,959	16,045	16,082	16,108	16,113	16,085	16,085	16,561			

In month		
Actual M8	Actual M9	Variance
14,162	14,245	83
893	956	64
347	374	27
15,402	15,575	173

Summary Financial Position

	In month			YTD - M1-M9			M1-M12
	Forecast	Actual	Variance	Forecast	Actual	Variance	Forecast
	£000	£000	£000	£000	£000	£000	£000
Patient Care Income	93,864	93,481	(383)	837,641	837,258	(383)	1,139,679
Other Income	11,706	12,954	1,248	106,884	108,132	1,248	143,196
Total Income	105,570	106,434	865	944,525	945,390	865	1,282,875
Pay Costs	(64,802)	(64,778)	24	(567,497)	(567,473)	24	(766,154)
Non-Pay Costs	(37,406)	(36,519)	886	(323,706)	(322,820)	886	(454,987)
Total Costs	(102,207)	(101,297)	910	(891,203)	(890,293)	910	(1,221,141)
EBITDA	3,363	5,137	1,775	53,322	55,097	1,775	61,734
Non-Operating Costs	(5,130)	(5,728)	(599)	(43,827)	(44,426)	(599)	(60,008)
Retained Surplus/(Deficit)	(1,767)	(591)	1,176	9,494	10,670	1,176	1,726
Donated Assets	(73)	(1,261)	(1,188)	133	(1,056)	(1,188)	(1,275)
Net Surplus/(Deficit)	(1,841)	(1,853)	(12)	9,627	9,615	(12)	450
Surplus/(Deficit)	(1,841)	(1,853)	(12)	9,627	9,615	(12)	450
Less Profit On Disposal	0	0	0	(450)	(450)	0	(450)
Control Total Surplus/(Deficit)	(1,841)	(1,853)	(12)	9,177	9,165	(12)	0

Comments – In Month – Variance & Year To Date (YTD) - Variance

- Total income of £0.9mF reflects £1.4mF Children's Hospitals income (£1.4m), which is offset by the donated assets adjustment. The patient care income of £0.4mA relates to Excluded Drugs and Devices.
- Pay position in line with forecast.
- Non Pay position of £0.9mF reflects ERF underspend of £0.3mF, marginal cost of £0.2mF and drugs £0.6mF offset by Winter £0.2mA.
- Non-Operating costs of £0.6mA reflects increased depreciation of £0.4mA and PDC dividends payable £0.2mA.

Comments – Forecast M1-M12


- The Trust full year forecast is at breakeven after adjusting for a return of £9m of income to the System. The forecast has based on CMG workforce changes and delivery of activity plans including Winter and Elective Recovery Plans.

2021/22 Actuals and Forecast

	Actual	Actual	Actual	Actual	Actual	Actual	Actual	H2		H2 In month (December)			YTD - M1-M9			M1-M12
	Apr-21	May-21	Jun-21	Jul-21	Aug-21	Sep-21	H1	Oct-21	Nov-21	Forecast	Actual	Variance	Forecast	Actual	Variance	Forecast
	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000
Patient Care Income	81,516	79,970	111,758	90,805	90,906	100,450	555,405	94,004	94,369	93,864	93,481	(383)	837,641	837,258	(383)	1,139,679
Other Income	21,114	22,597	(8,211)	11,329	11,000	12,350	70,178	12,220	12,780	11,706	12,954	1,248	106,884	108,132	1,248	143,196
Total Income	102,630	102,567	103,547	102,133	101,906	112,800	625,583	106,224	107,149	105,570	106,434	865	944,525	945,390	865	1,282,875
Pay Costs	(61,744)	(61,297)	(61,107)	(60,841)	(61,330)	(71,639)	(377,957)	(63,831)	(60,907)	(64,802)	(64,778)	24	(567,497)	(567,473)	24	(766,154)
Non-Pay Costs	(35,854)	(33,905)	(36,108)	(36,541)	(33,469)	(37,235)	(213,112)	(34,140)	(39,048)	(37,406)	(36,519)	886	(323,706)	(322,820)	886	(454,987)
Total Costs	(97,598)	(95,202)	(97,215)	(97,382)	(94,799)	(108,873)	(591,069)	(97,972)	(99,956)	(102,207)	(101,297)	910	(891,203)	(890,293)	910	(1,221,141)
EBITDA	5,033	7,365	6,332	4,751	7,107	3,927	34,514	8,252	7,193	3,363	5,137	1,775	53,322	55,097	1,775	61,734
Non-Operating Costs	(4,934)	(3,359)	(4,375)	(5,403)	(4,722)	(5,624)	(28,416)	(5,051)	(5,231)	(5,130)	(5,728)	(599)	(43,827)	(44,426)	(599)	(60,008)
Retained Surplus/(Deficit)	99	4,006	1,957	(651)	2,385	(1,697)	6,098	3,201	1,963	(1,767)	(591)	1,176	9,494	10,670	1,176	1,726
Donated Assets	47	108	32	(698)	228	65	(219)	272	152	(73)	(1,261)	(1,188)	133	(1,056)	(1,188)	(1,275)
Net Surplus/(Deficit)	145	4,114	1,989	(1,349)	2,613	(1,632)	5,879	3,473	2,115	(1,841)	(1,853)	(12)	9,627	9,615	(12)	450
Surplus/(Deficit)	145	4,114	1,989	(1,349)	2,613	(1,632)	5,879	3,473	2,115	(1,841)	(1,853)	(12)	9,627	9,615	(12)	450
Profit On Disposal	0	(450)	0	0	0	0	(450)	0	0	0	0	0	(450)	(450)	0	(450)
Control Total Surplus/(Deficit)	145	3,664	1,989	(1,349)	2,613	(1,632)	5,429	3,473	2,115	(1,841)	(1,853)	(12)	9,177	9,165	(12)	0

- The pay and non-pay expenditure profile reflects CMG workforce changes and delivery of activity plans.
- The September pay expenditure position reflects the impact of the backdated pay award.

Bridge Movement Between M9 Forecast vs M9 Actuals - £k



Break Down of Actuals and Forecast (1/3)

	In month			YTD			M1-M12
	Forecast	Actual	Variance	Forecast	Actual	Variance	Forecast at M9
	£000	£000	£000	£000	£000	£000	£000
Baseline							
Patient Care Income	93,833	93,444	(390)	837,498	837,108	(390)	1,134,822
Other Income	10,976	12,477	1,501	99,252	100,753	1,501	133,671
Total Income	104,809	105,921	1,111	936,750	937,862	1,111	1,268,493
Pay Costs	(64,377)	(64,776)	(399)	(566,903)	(567,302)	(399)	(763,266)
Non Pay Costs	(37,200)	(36,599)	601	(322,787)	(322,185)	601	(452,641)
Total Costs	(101,578)	(101,375)	202	(889,690)	(889,487)	202	(1,215,907)
EBITDA	3,232	4,546	1,314	47,061	48,375	1,314	52,585
Non-Operating Costs	(5,130)	(5,728)	(599)	(43,827)	(44,426)	(599)	(60,008)
Retained Surplus/(Deficit)	(1,898)	(1,183)	715	3,234	3,949	715	(7,423)
Donated Assets	(73)	(1,261)	(1,188)	133	(1,056)	(1,188)	(1,275)
Net Surplus/(Deficit)	(1,971)	(2,444)	(473)	3,366	2,893	(473)	(8,698)
Surplus/(Deficit)	(1,971)	(2,444)	(473)	3,366	2,893	(473)	(8,698)
COVID							
Patient Care Income	1	1	(0)	9	9	(0)	12
Other Income	606	323	(283)	5,565	5,282	(283)	7,099
Total Income	607	324	(283)	5,574	5,291	(283)	7,111
Pay Costs	(417)	(262)	155	(4,171)	(4,016)	155	(5,178)
Non Pay Costs	(413)	(195)	217	(4,243)	(4,026)	217	(5,169)
Total Costs	(830)	(457)	373	(8,414)	(8,042)	373	(10,347)
EBITDA	(223)	(133)	90	(2,840)	(2,750)	90	(3,236)
Non-Operating Costs	0	0	0	0	0	0	0
Retained Surplus/(Deficit)	(223)	(133)	90	(2,840)	(2,750)	90	(3,236)
Donated Assets	0	0	0	0	0	0	0
Net Surplus/(Deficit)	(223)	(133)	90	(2,840)	(2,750)	90	(3,236)
Surplus/(Deficit)	(223)	(133)	90	(2,840)	(2,750)	90	(3,236)

Break Down of Actuals and Forecast (2/3)

	In month			YTD			M1-M12
	Forecast	Actual	Variance	Forecast	Actual	Variance	Forecast at M9
	£000	£000	£000	£000	£000	£000	£000
Restoration and Recovery							
Patient Care Income	0	0	0	0	0	0	0
Other Income	0	0	0	0	0	0	0
Total Income	0	0	0	0	0	0	0
Pay Costs	(20)	(20)	0	(139)	(139)	0	(199)
Non Pay Costs	(241)	(235)	6	(2,107)	(2,101)	6	(2,802)
Total Costs	(261)	(255)	6	(2,246)	(2,240)	6	(3,001)
EBITDA	(261)	(255)	6	(2,246)	(2,240)	6	(3,001)
Non-Operating Costs	0	0	0	0	0	0	0
Retained Surplus/(Deficit)	(261)	(255)	6	(2,246)	(2,240)	6	(3,001)
Donated Assets	0	0	0	0	0	0	0
Net Surplus/(Deficit)	(261)	(255)	6	(2,246)	(2,240)	6	(3,001)
Surplus/(Deficit)	(261)	(255)	6	(2,246)	(2,240)	6	(3,001)
Winter Presuures							
Patient Care Income	0	0	0	0	0	0	4,617
Other Income	0	0	0	0	0	0	0
Total Income	0	0	0	0	0	0	4,617
Pay Costs	(442)	(236)	206	(782)	(575)	206	(2,984)
Non Pay Costs	51	(101)	(152)	(393)	(546)	(152)	(1,683)
Total Costs	(391)	(337)	54	(1,175)	(1,121)	54	(4,667)
EBITDA	(391)	(337)	54	(1,175)	(1,121)	54	(50)
Non-Operating Costs	0	0	0	0	0	0	0
Retained Surplus/(Deficit)	(391)	(337)	54	(1,175)	(1,121)	54	(50)
Donated Assets	0	0	0	0	0	0	0
Net Surplus/(Deficit)	(391)	(337)	54	(1,175)	(1,121)	54	(50)
Surplus/(Deficit)	(391)	(337)	54	(1,175)	(1,121)	54	(50)

Break Down of Actuals and Forecast (3/3)

	In month			YTD			FOT
	Forecast	Actual	Variance	Forecast	Actual	Variance	Forecast at M9
	£000	£000	£000	£000	£000	£000	£000
CIP Savings							
Patient Care Income	29	36	7	134	141	7	228
Other Income	124	153	29	2,067	2,096	29	2,426
Total Income	154	190	36	2,201	2,237	36	2,654
Pay Costs	455	516	61	4,498	4,559	61	5,473
Non Pay Costs	398	611	214	5,824	6,038	214	7,308
Total Costs	853	1,128	275	10,322	10,596	275	12,781
EBITDA	1,006	1,317	311	12,522	12,833	311	15,436
Non-Operating Costs	0	0	0	0	0	0	0
Retained Surplus/(Deficit)	1,006	1,317	311	12,522	12,833	311	15,436
Donated Assets	0	0	0	0	0	0	0
Net Surplus/(Deficit)	1,006	1,317	311	12,522	12,833	311	15,436
Surplus/(Deficit)	1,006	1,317	311	12,522	12,833	311	15,436
Total							
Patient Care Income	93,864	93,481	(383)	837,641	837,258	(383)	1,139,679
Other Income	11,706	12,954	1,248	106,884	108,132	1,248	143,196
Total Income	105,570	106,434	865	944,525	945,390	865	1,282,875
Pay Costs	(64,802)	(64,778)	24	(567,497)	(567,473)	24	(766,154)
Non Pay Costs	(37,406)	(36,519)	886	(323,706)	(322,820)	886	(454,987)
Total Costs	(102,207)	(101,297)	910	(891,203)	(890,293)	910	(1,221,141)
EBITDA	3,363	5,137	1,775	53,322	55,097	1,775	61,734
Non-Operating Costs	(5,130)	(5,728)	(599)	(43,827)	(44,426)	(599)	(60,008)
Retained Surplus/(Deficit)	(1,767)	(591)	1,176	9,494	10,670	1,176	1,726
Donated Assets	(73)	(1,261)	(1,188)	133	(1,056)	(1,188)	(1,275)
Net Surplus/(Deficit)	(1,841)	(1,853)	(12)	9,627	9,615	(12)	450
Surplus/(Deficit)	(1,841)	(1,853)	(12)	9,627	9,615	(12)	450
Profit On Disposal	0	0	0	(450)	(450)	0	(450)
Control Total Surplus/(Deficit)	(1,841)	(1,853)	(12)	9,177	9,165	(12)	0

Forecast Outturn Analysis

	M1-M12 Forecast @ M8 £'000							M1-M12 Actuals/FOT @ M9 £'000							M1-M12 - Actuals/FOT Variance @ M9 £'000						
	Covid-19	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total	Covid-19	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total	Covid-19	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total
NHS Patient Income	12	0	3,287	221	0	1,128,255	1,131,775	12	0	4,617	228	0	1,134,822	1,139,679	(0)	0	1,330	7	0	6,567	7,904
Other Operating Income	7,382	0	0	1,001	1,426	131,769	141,578	7,099	0	0	694	1,732	133,671	143,196	(283)	0	0	(307)	307	1,902	1,618
Total Income	7,394	0	3,287	1,222	1,426	1,260,023	1,273,353	7,111	0	4,617	922	1,732	1,268,493	1,282,875	(283)	0	1,330	(300)	307	8,469	9,522
Non Agency Pay	(3,147)	(199)	(2,502)	3,726	1,382	(741,595)	(742,335)	(3,096)	(199)	(2,442)	3,755	1,450	(744,071)	(744,604)	51	0	60	29	67	(2,475)	(2,269)
Agency Pay	(2,276)	0	(574)	261	(1)	(19,176)	(21,767)	(2,081)	0	(542)	225	43	(19,195)	(21,551)	195	0	32	(35)	44	(19)	217
Non-pay	(5,481)	(2,808)	(1,024)	4,622	2,409	(447,214)	(449,496)	(5,169)	(2,802)	(1,683)	4,675	2,633	(452,641)	(454,987)	312	6	(659)	53	224	(5,427)	(5,491)
Total Operating Costs	(10,905)	(3,007)	(4,100)	8,609	3,791	(1,207,986)	(1,213,598)	(10,347)	(3,001)	(4,667)	8,656	4,126	(1,215,907)	(1,221,141)	558	6	(567)	47	335	(7,921)	(7,543)
EBITDA	(3,511)	(3,007)	(813)	9,831	5,216	52,038	59,755	(3,236)	(3,001)	(50)	9,578	5,858	52,585	61,734	275	6	762	(253)	642	548	1,979
Non Operating Costs	0	0	0	0	0	(59,217)	(59,217)	0	0	0	0	0	(60,008)	(60,008)	0	0	0	0	0	(791)	(791)
Retained Surplus/(Deficit)	(3,511)	(3,007)	(813)	9,831	5,216	(7,179)	538	(3,236)	(3,001)	(50)	9,578	5,858	(7,423)	1,726	275	6	762	(253)	642	(243)	1,188
Donated Assets	0	0	0	0	0	(87)	(87)	0	0	0	0	0	(1,275)	(1,275)	0	0	0	0	0	(1,188)	(1,188)
Net Surplus/(Deficit)	(3,511)	(3,007)	(813)	9,831	5,216	(7,267)	450	(3,236)	(3,001)	(50)	9,578	5,858	(8,698)	450	275	6	762	(253)	642	(1,432)	(0)
Profit On Disposal	0	0	0	0	0	(450)	(450)	0	0	0	0	0	(450)	(450)	0	0	0	0	0	0	0
Control Total Surplus/(Defic	(3,511)	(3,007)	(813)	9,831	5,216	(7,717)	0	(3,236)	(3,001)	(50)	9,578	5,858	(9,148)	0	275	6	762	(253)	642	(1,432)	(0)

	YTD Forecast @ M8 £'000							YTD Actuals @ M9 £'000							YTD - Actuals/FOT Variance @ M9 £'000						
	Covid-19	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total	Covid-19	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total	Covid-19	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total
NHS Patient Income	9	0	0	134	0	837,498	837,641	9	0	0	141	0	837,108	837,258	(0)	0	0	7	0	(390)	(383)
Other Operating Income	5,565	0	0	673	1,394	99,252	106,884	5,282	0	0	596	1,500	100,753	108,132	(283)	0	0	(77)	107	1,501	1,248
Total Income	5,574	0	0	807	1,394	936,750	944,525	5,291	0	0	736	1,500	937,862	945,390	(283)	0	0	(70)	107	1,111	865
Non Agency Pay	(2,470)	(139)	(583)	3,162	1,162	(553,241)	(552,110)	(2,419)	(139)	(410)	3,189	1,194	(553,730)	(552,316)	51	0	173	27	32	(489)	(206)
Agency Pay	(1,701)	0	(198)	175	(1)	(13,662)	(15,387)	(1,597)	0	(165)	177	(1)	(13,572)	(15,157)	105	0	33	2	0	90	230
Non-pay	(4,243)	(2,107)	(393)	3,404	2,420	(322,787)	(323,706)	(4,026)	(2,101)	(546)	3,441	2,597	(322,185)	(322,820)	217	6	(152)	37	177	601	886
Total Operating Costs	(8,414)	(2,246)	(1,175)	6,742	3,580	(889,690)	(891,203)	(8,042)	(2,240)	(1,121)	6,807	3,789	(889,487)	(890,293)	373	6	54	66	209	202	910
EBITDA	(2,840)	(2,246)	(1,175)	7,548	4,974	47,061	53,322	(2,750)	(2,240)	(1,121)	7,544	5,290	48,375	55,097	90	6	54	(5)	316	1,314	1,775
Non Operating Costs	0	0	0	0	0	(43,827)	(43,827)	0	0	0	0	0	(44,426)	(44,426)	0	0	0	0	0	(599)	(599)
Retained Surplus/(Deficit)	(2,840)	(2,246)	(1,175)	7,548	4,974	3,234	9,494	(2,750)	(2,240)	(1,121)	7,544	5,290	3,949	10,670	90	6	54	(5)	316	715	1,176
Donated Assets	0	0	0	0	0	133	133	0	0	0	0	0	(1,056)	(1,056)	0	0	0	0	0	(1,188)	(1,188)
Net Surplus/(Deficit)	(2,840)	(2,246)	(1,175)	7,548	4,974	3,366	9,627	(2,750)	(2,240)	(1,121)	7,544	5,290	2,893	9,615	90	6	54	(5)	316	(473)	(12)
Profit On Disposal	0	0	0	0	0	(450)	(450)	0	0	0	0	0	(450)	(450)	0	0	0	0	0	0	0
Control Total Surplus/(Defic	(2,840)	(2,246)	(1,175)	7,548	4,974	2,916	9,177	(2,750)	(2,240)	(1,121)	7,544	5,290	2,443	9,165	90	6	54	(5)	316	(473)	(12)

	M8 Forecast @ M8 £'000							M9 Actuals £'000							M9 FOT Variance £'000						
	Covid-19	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total	Covid-19	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total	Covid-19	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total
NHS Patient Income	1	0	0	29	0	93,833	93,864	1	0	0	36	0	93,444	93,481	(0)	0	0	7	0	(390)	(383)
Other Operating Income	606	0	0	114	11	10,976	11,706	323	0	0	36	117	12,477	12,954	(283)	0	0	(77)	107	1,501	1,248
Total Income	607	0	0	143	11	104,809	105,570	324	0	0	72	117	105,921	106,434	(283)	0	0	(70)	107	1,111	865
Non Agency Pay	(226)	(20)	(377)	325	102	(62,548)	(62,744)	(175)	(20)	(204)	352	134	(63,037)	(62,950)	51	0	173	27	32	(489)	(206)
Agency Pay	(192)	0	(66)	28	0	(1,829)	(2,058)	(87)	0	(32)	30	0	(1,739)	(1,828)	105	0	33	2	0	90	230
Non-pay	(413)	(241)	51	391	7	(37,200)	(37,406)	(195)	(235)	(101)	427	184	(36,599)	(36,519)	217	6	(152)	37	177	601	886
Total Operating Costs	(830)	(261)	(391)	744	109	(101,578)	(102,207)	(457)	(255)	(337)	809	318	(101,375)	(101,297)	373	6	54	66	209	202	910
EBITDA	(223)	(261)	(391)	887	120	3,232	3,363	(133)	(255)	(337)	882	435	4,546	5,137	90	6	54	(5)	316	1,314	1,775
Non Operating Costs	0	0	0	0	0	(5,130)	(5,130)	0	0	0	0	0	(5,728)	(5,728)	0	0	0	0	0	(599)	(599)
Retained Surplus/(Deficit)	(223)	(261)	(391)	887	120	(1,898)	(1,767)	(133)	(255)	(337)	882	435	(1,183)	(591)	90	6	54	(5)	316	715	1,176
Donated Assets	0	0	0	0	0	(73)	(73)	0	0	0	0	0	(1,261)	(1,261)	0	0	0	0	0	(1,188)	(1,188)
Net Surplus/(Deficit)	(223)	(261)	(391)	887	120	(1,971)	(1,841)	(133)	(255)	(337)	882	435	(2,444)	(1,853)	90	6	54	(5)	316	(473)	(12)
Profit On Disposal	0	0	0	0	0	0	0	0	0	0	0	0	(0)	(0)	0	0	0	0	0	0	0
Control Total Surplus/(Defic	(223)	(261)	(391)	887	120	(1,971)	(1,841)	(133)	(255)	(337)	882	435	(2,444)	(1,853)	90	6	54	(5)	316	(473)	(12)

Update on CIP

Planned	Planned £'000												Year to Date £'000
	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	
1. CIP Budget Reduction - Current year new schemes	525	618	703	588	650	704	972	994	1,002	1,026	1,025	1,029	6,751
2. CIP Budget Reduction - Prior Year Full Year Effect	78	79	80	81	81	81	68	68	63	62	62	62	679
5. Other Run Rate Reduction	98	172	182	105	129	149	554	297	288	138	138	141	1,975
Total Cash Releasing	701	869	965	774	860	933	1,594	1,359	1,353	1,226	1,225	1,232	9,405
3. Cost Avoidance	143	16	23	23	23	23	23	24	23	23	23	23	322
4. Productivity Improvement	58	59	62	63	64	67	564	90	90	90	90	90	1,117
Total Non - Cash Releasing	201	76	85	86	87	90	587	115	113	113	113	113	1,439
Total All	902	945	1,050	860	948	1,024	2,181	1,473	1,466	1,339	1,338	1,345	10,844

Actual / Forecast (Risk Adjusted)	Actual / Forecast (Risk Adjusted) £'000												Year to Date £'000
	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	
1. CIP Budget Reduction - Current year new schemes	239	1,464	577	581	754	776	1,087	771	740	663	620	604	6,988
2. CIP Budget Reduction - Prior Year Full Year Effect	80	75	77	77	77	78	62	65	60	59	59	59	651
5. Other Run Rate Reduction	254	321	410	242	2,070	375	605	399	517	203	158	177	5,193
Total Cash Releasing	574	1,861	1,064	900	2,901	1,228	1,753	1,236	1,317	925	837	840	12,833
3. Cost Avoidance	187	31	44	33	66	17	16	138	74	72	72	72	605
4. Productivity Improvement	-	-	361	190	163	163	960	265	258	205	205	205	2,360
Total Non - Cash Releasing	187	31	405	223	229	180	975	403	333	277	277	277	2,965
Total All	760	1,891	1,469	1,123	3,130	1,408	2,729	1,638	1,649	1,202	1,114	1,117	15,798

The risk adjusted schemes figures are valued in the above table at 100% (Green), 25% (Amber) and 0% (Red)


Variance to Plan (Risk Adjusted)	Variance to Plan (Risk Adjusted) £'000												Year to Date £'000
	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	
1. CIP Budget Reduction - Current year new schemes	(286)	846	(126)	(7)	104	72	115	(223)	(262)	(362)	(405)	(425)	238
2. CIP Budget Reduction - Prior Year Full Year Effect	2	(3)	(3)	(4)	(4)	(4)	(6)	(3)	(3)	(2)	(2)	(2)	(28)
5. Other Run Rate Reduction	157	149	228	136	1,941	226	50	103	229	65	19	35	3,219
Total Cash Releasing	(127)	992	99	126	2,041	295	159	(123)	(36)	(300)	(388)	(392)	3,428
3. Cost Avoidance	43	14	22	10	43	(6)	(7)	114	51	49	49	49	283
4. Productivity Improvement	(58)	(59)	299	127	99	96	396	175	168	115	115	115	1,243
Total Non - Cash Releasing	(14)	(45)	320	137	142	90	388	288	220	164	164	164	1,526
Total All	(141)	947	419	263	2,183	384	547	165	183	(137)	(224)	(228)	4,954

SLR/PLICS Summary Position (M8)


Net Surplus/(Deficit) by Point of Delivery

Point of Delivery	Activity	Income	Total Costs	Direct	Indirect	Contribution	Overheads	Net Surplus / Deficit
Accident & Emergency	177,966	£30,835,763	£47,699,838	£31,136,562	£6,583,113	(£6,883,913)	£9,980,163	(£16,864,075)
Daycase	61,570	£57,786,111	£62,775,993	£38,084,903	£11,651,100	£8,050,107	£13,039,990	(£4,989,883)
Elective Inpatient	10,856	£60,270,434	£81,385,579	£46,404,887	£16,284,401	(£2,418,853)	£18,696,292	(£21,115,145)
Non-Elective Inpatient	136,073	£260,780,330	£325,459,106	£211,810,146	£38,174,292	£10,795,892	£75,474,668	(£64,678,776)
Outpatient First Attendance	153,766	£37,099,401	£39,164,095	£24,120,481	£5,049,721	£7,929,199	£9,993,894	(£2,064,694)
Outpatient Follow-up	424,877	£61,175,664	£85,217,343	£58,799,322	£10,031,160	(£7,654,818)	£16,386,862	(£24,041,679)
Outpatient Procedure	118,273	£31,422,785	£33,442,859	£21,503,289	£4,234,720	£5,684,777	£7,704,850	(£2,020,074)
Dialysis	135,332	£20,730,690	£21,291,689	£15,296,134	£808,200	£4,626,356	£5,187,355	(£560,999)
Direct Access	-	£16,369,685	£20,359,800	£5,102,956	£11,432,784	(£166,054)	£3,824,061	(£3,990,115)
Homecare Drugs	-	£26,508,395	£26,305,522	£24,808,825	£1,130,255	£569,314	£366,441	£202,873
Research	-	£48,843,847	£48,786,092	£1,577,688	£47,058,490	£207,669	£149,914	£57,756
Other	59,711	£31,595,612	£34,912,212	£23,599,159	£3,948,693	£4,047,760	£7,364,360	(£3,316,600)
Top-up Income		£85,726,897	£0	£0	£0	£85,726,897	£0	£85,726,897
Balance of Block after PbR allocation		£68,673,658	£0	£0	£0	£68,673,658	£0	£68,673,658
Total	1,278,424	£837,819,272	£826,800,129	£502,244,351	£156,386,929	£179,187,991	£168,168,848	£11,019,143

Cost/Income/Net Profit by CMG (exc. block adjustment)



Portfolio Matrix



SLR/PLICS Summary Position Notes (M8)

- Income allocations to CMG are based on activity x price under a PBR model.
- Patient Level costing is undertaken in accordance with the NHS Approved Costing Guidance and can be aggregated to show financial performance at many levels. This costing data is used internally and externally as part of the National Cost Collection (prev. Reference Cost Submission). It uses information systems and recorded activity (such as Ward, Theatre, Drug and diagnostic records) as drivers to ensure that costs recorded in the ledger are assigned to the patients and services where resources are used.
- Costs are classified into Direct, Indirect and Overheads. Indirect costs in the outputs include, management and admin teams and some other services that support the front line. Overheads include all corporate directorates, Estates & Facilities and 'Central' Costs such as Depreciation, PDC and other provisions.
- Activity is imported from our core activity systems including HISS (IP and OP), Nervecentre (AE) and Proton (Dialysis) and is reconciled each year to the national HES submissions. 2021/22 In comparison to 2019/20, Planned Inpatient activity (DC and EL) are down by over 20%, New Outpatients are down by c.17% and procedures are down by c.14%
- The data shows us that the Trust is currently generating deficits across most points of delivery, with a large element due to a reduction in activity whilst fixed costs remain. These deficits at a Point of Delivery and Speciality level are negated by the Block Contract and Top Up income that are sitting centrally in other.
- The portfolio Matrix shows the 'profitability' of each CMG alongside its comparison to the national average prices from 2019/20. Most CMG's show a position favourable to the national average whilst running at a negative margin in the current year. This will partially be due to the fact that activity (and assumed income) this year is reduced, whilst fixed costs remain and the latest comparison to national averages is 'pre-covid'.
- It should be noted that the 2019/20 National Cost Collection results are an estimate, based on draft accounts.

Statement of Financial Position

	M9 YTD					
	2021-2022 Opening	30-Nov-21	31-Dec-21	Movement	Prior Year Adjustments	Current Month Movement
Non current assets		£000	£000	£000	£000	£000
Intangible assets	9,262	7,631	7,427	(204)	(178)	(26)
Property, plant and equipment	606,518	609,803	610,637	833	(1,340)	2,173
Other non-current assets	4,728	4,448	4,448	0	0	0
Total non-current assets	620,508	621,883	622,513	630	(1,517)	2,147
Current assets						
Inventories	20,837	21,524	22,910	1,386	0	1,386
Trade and other receivables	37,903	36,877	39,069	2,192	0	2,192
Cash and cash equivalents	90,033	102,240	96,611	(5,629)	0	(5,629)
Total current assets	148,773	160,641	158,590	(2,050)	0	(2,050)
Current liabilities						
Trade and other payables	(114,665)	(91,789)	(95,340)	(3,551)	0	(3,551)
Borrowings / leases	(6,481)	(6,481)	(6,481)	0	232	(232)
Accruals	(9,602)	(19,015)	(17,845)	1,170	0	1,170
Deferred income	(2,975)	(11,712)	(7,759)	3,953	0	3,953
Dividend payable		(4,477)	(5,974)	(1,497)	0	(1,497)
Provisions < 1 year	(15,203)	(14,920)	(14,933)	(13)	(1,838)	1,825
Total current liabilities	(148,925)	(148,393)	(148,332)	61	(1,606)	1,668
Net current assets / (liabilities)	(153)	12,248	10,259	(1,989)	(1,606)	(383)
Non-current liabilities						
Borrowings / leases	(7,547)	(7,482)	(6,715)	768	566	202
Provisions for liabilities & charges	(5,870)	(5,870)	(5,870)	0	0	0
Total non-current liabilities	(13,417)	(13,352)	(12,585)	768	566	202
Total assets employed	606,938	620,778	620,186	(592)	(2,558)	1,966
Public dividend capital	742,817	745,394	745,394	0	0	0
Revaluation reserve	189,145	189,145	189,145	0	0	0
Income and expenditure reserve	(325,025)	(313,761)	(314,353)	(592)	(2,558)	1,966
Total taxpayers equity	606,938	620,778	620,186	(592)	(2,558)	1,966

The Statement of Financial Position (SOFP) at 31 December 2021 is presented in the table opposite. The balance sheet fully reflects the impact of 20/21 draft Accounts adjustments that are being finalised for audit review. The key movements in the balance sheet at M9 were as follows:

- **Non Current Assets**

PPE and intangible assets have increased by £2.1m mainly as a result additional capital spend of £4.7m, offset by depreciation and amortisation charges of £3.4m.

- **Working Capital**

Inventory – increased by £1.4m, mainly due to an increase in TGH drugs stock of £0.9m and an increase in cardiology stock of £0.3m. The build up of drug stock ahead of Christmas is part a expected business cycle and will reduce to normalised levels in January

Trade and other Receivables – increased by £2.2m, mainly as a consequence of a £1.9m increase in prepayments (including a £1.5m prepayment for consumables from our MES provider (Althea) and a £0.4m as a result of the phasing of the CNST premium); and a £1.5m recharge to the Leicester Hospitals Charity for their contribution to the Trust's EMCHC scheme. These increases were offset by a £0.9m reduction in sales ledger receivables, mainly driven by contract payments of £0.5m received from NHS England in December.

Trade and other payables and accruals – increased by £3.6m mainly due; to a £5.3m increase in GRNI accruals, a £1.5m increase in tax and social security payables; offset by a £1.3m reduction in purchase ledger payables.

Deferred Income balances – reduced by £4m, as December's LDA education and training levy income was reflected in the financial position

- **I&E Reserve**

The 2021/22 cumulative deficit on the I&E reserve increased by £0.6m, in line with the reported deficit delivered in December.

Cash Flow

Actual YTD						
Monthly cash flow(£000)	July	Aug	Sept	Oct	Nov	Dec
	"£000"	"£000"	"£000"	"£000"	"£000"	"£000"
Block payments-Other CCG	1,689	1,596	1,713	1,896	1,750	1,733
Block payments-Leic City CCG	15,743	12,741	15,719	21,824	17,058	20,325
Block payments-Leic West CCG	15,103	13,214	15,103	16,864	15,278	15,075
Block payments-Leic East CCG	14,245	12,644	14,346	15,906	15,188	13,902
Block payments-NHS England	32,032	32,303	33,629	33,433	21,500	30,388
System Top Up	10,218	10,218	10,218	6,467	10,218	11,517
COVID-19 top up	3,839	3,839	3,839	4,957	3,839	0
Health education payments	8,779	0	0	0	16,469	0
Other NHS income	2,595	673	2,833	3,219	3,950	3,189
Research	2,187	2,187	2,334	2,187	2,187	2,161
Capital Receipts	0	0	0	0	0	0
TMP	3,002	3,412	3,966	3,078	3,893	3,229
PDC Drawdown				0	2,577	
Other non-NHS income	5,585	7,390	4,204	4,380	4,290	5,075
Total receipts	115,017	100,217	107,904	114,211	118,197	106,594
Salaries and wages	(58,549)	(58,335)	(64,895)	(65,465)	(60,802)	(62,356)
Creditor payments	(61,339)	(39,838)	(41,763)	(43,719)	(45,232)	(45,553)
PDC dividend	0	0	(7,572)	0	0	0
NHSE/I						
TMP	(3,426)	(2,458)	(4,478)	(3,066)	(3,284)	(4,289)
Total payments	(123,314)	(100,631)	(118,708)	(112,250)	(109,318)	(112,198)
Month end balance	(8,297)	(414)	(10,804)	1,961	8,879	(5,604)
Cash in transit and cash in hand adjustment	(49)	146	260	276	127	(26)
Balance brought forward	110,156	101,810	101,542	90,997	93,234	102,240
Balance carried forward	101,810	101,542	90,997	93,234	102,240	96,611

The Trust maintained a strong cash position at the end of December (£96.6m).

Cash reserves decreased by £5.6m in December, driven by £106.6m receipts less £112.2m payments.

Receipts were £11.6m lower than the prior month mainly due to the quarterly receipt of £16.5m for education and training, PDC drawdown of £2.6m and £3.8m Covid 19 top-up received in November. These items were partly offset in December by an increase in block payments from NHS England of £8.9m and from local CCGs of £1.8m, supplemented by an increase in other non-NHS income of £0.8m.

Purchase ledger payment runs of £45.5m were consistent with November (£45.2m), and December saw increases in salary payments of £1.6m and TGH related payments of £1.0m.

The Trust will continue to benefit from block and top up funding for the remainder of the financial year.

The Trust's Cash Committee is meeting on a bi-weekly basis. Each meeting receives a cash report which contains a brief narrative summary and supporting graphs/tables showing the cash position against the forecast position, a cash balance reconciliation which identifies what the Trust's underlying cash balance is after items such as capital creditors and a summary of receipts/payments. The cash report will be enhanced through the use of sensitivity analysis for key assumptions and inputs to show the potential cash flow impact for a variety of movements, in future months.

Working Capital

	Total	0 to 30 days	31 to 60 days	61 to 90 days	Over 90 days	Percentage over 90 days
December 2021	£000	£000	£000	£000	£000	%
Non-NHS receivables	6,638	1,411	750	518	3,959	60%
NHS receivables	3,421	2,137	346	430	508	15%
Total receivables	10,059	3,548	1,096	948	4,467	44%
Non-NHS payables	16,533	10,412	2,678	825	2,618	16%
NHS payables	5,009	2,150	1,361	235	1,263	25%
Total payables	21,542	12,562	4,039	1,060	3,881	18%

November 2021	£000	£000	£000	£000	£000	%
Non-NHS receivables	7,138	1,845	1,095	428	3,770	53%
NHS receivables	3,784	1,874	1,126	118	666	18%
Total receivables	10,922	3,719	2,221	546	4,436	41%
Non-NHS payables	17,637	12,417	1,876	1,180	2,164	12%
NHS payables	5,195	2,281	272	1,425	1,217	23%
Total payables	22,832	14,698	2,148	2,605	3,381	15%

Over 90 Receivables	Apr 21 (£000s)	July 21 (£000s)	Oct 21 (£000s)	Nov 21 (£000s)	Dec 21 (£000s)	Change (£000s)	Instalment Plan (£000s)	Bad Debt Provision (£000s)
Overseas Visitors	1,732	1,795	1,719	1,719	1,793	74	442	1,021
Private Patients	837	891	1,016	979	987	8	0	814
Universities	629	666	278	177	337	160	0	63
Salary overpayment	372	416	446	464	453	(11)	244	108
Other	291	295	174	204	154	(50)	1	85
NHS Providers	175	290	493	496	411	(85)	0	0
Other NHS	175	206	222	210	220	10	0	167
Commissioner SLAs	81	486	182	170	96	(74)	0	0
CCGs	31	17	3	0	0	0	0	0
Local Authority	29	11	49	7	4	(3)	0	5
Accommodation Charges	12	11	11	10	11	1	4	2
Total	4,364	5,084	4,593	4,436	4,466	30	691	2,265
Total Debt	9,171	19,948	28,759	10,922	10,058	(864)		

Aged Debt (Sales Ledger)

Receivables

The sales ledger receivables position is the subject of a deep dive paper on the agenda, with a specific on private patients and overseas visitors.

Sales ledger debt reduced by £0.9m in December, as we received settlement of £0.5m from NHS England against contract liabilities, which was outstanding at the end of November.

There was a minimal increase in over 90 day debt increased of £30k. The over 90 day debt balance includes £0.7m on payment instalment plans and £2.3m is included within the Trust's bad debt provision. The composition of the aged debt and actions being taken to reduce this value is discussed in more detail within the debtors deeper dive paper.

Payables

In month payables fell by £1.3m primarily due to a £1.1m reduction in non-NHS payables, although there was also a small increase of 3% in aged creditors over 90 days.

Overall there were no significant movements in payables in month 9 to report, with the value of creditor payments were consistent with the prior month. We made £45.5m of creditor payments in December compared to £45.2m in November.

Working Capital

	Target	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21	Sep-21	Oct-21	Nov-21	Dec-21
BPPC (cumulative)											
Value %	95%	92%	93%	94%	93%	93%	94%	94%	94%	94%	94%
Volume %	95%	91%	96%	92%	88%	91%	90%	91%	91%	92%	92%
BPPC (SMEs) paid within 30 days											
Value %	100%	79%	88%	91%	82%	83%	86%	91%	91%	91%	91%
Volume %	100%	86%	83%	89%	84%	86%	86%	83%	85%	84%	86%
BPPC (SMEs) paid within 5 days											
Value %	90%	17%	14%	16%	25%	35%	25%	21%	17%	13%	14%
Volume %	90%	22%	20%	32%	27%	33%	29%	29%	29%	25%	24%

BPPC

Cumulative YTD performance of 94% for value and 92% for volume of invoices processed was achieved in December.

Capital Programme

Application of funds			Source of funds							YTD Position		
Area	Scheme	Total	Internally funded	STP PDC	PDC	Charitable Funds	Proceeds from asset disposal	System reallocation	Carry forward PDC - EUC	M8 YTD Forecast	M9 YTD Actuals	(Under)/Over spend
		£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
Reconfiguration	Reconfiguration main programme	8,566	3,284		2,577		2,705			5,352	5,577	225
	Scheme outside of main programme	77	0				77			37	0	(37)
	Reconfiguration precommitment - nephrology	1,343	1,343							428	49	(380)
	Reconfiguration precommitment - ICU	1,149	1,149							300	316	15
	Reconfiguration precommitment - EMCHC	1,852	0			1,852				1,894	1,842	(52)
Total Reconfiguration		12,987	5,776	0	2,577	1,852	2,782	0	0	8,012	7,783	(229)
MEE	MEE Medical Equipment Executive	1,626	1,626							773	763	(10)
Total MEE		1,626	1,626	0	0	0	0	0	0	773	763	(10)
MES	MES Replacement	3,249	3,249							626	144	(482)
	MES Enabling Costs of MES	1,207	1,207							266	52	(214)
	MES precommitment for Equipment	3,302	2,353	949	0					2,820	3,302	482
	MES precommitment for Enabling costs	1,549	1,549							1,591	1,549	(42)
Total MES		9,307	8,358	949	0	0	0	0	0	5,303	5,047	(256)
IM&T	IM&T eHospital	1,201	1,201							897	869	(28)
	eEquip	2,301	2,301							1,326	1,243	(83)
	NEW Digital Aspirant	2,400					2,400			1,435	1,378	(57)
	IM&T schemes	5,320	4,470		850					2,047	1,903	(144)
Total IM&T		11,222	7,972	0	850	0	2,400	0	0	5,705	5,393	(312)
Estates and Facilities	Backlog maintenance	9,146	9,146							5,525	5,409	(116)
	Estates schemes	4,968	2,541				1,605		822	575	306	(270)
Total Estates and Facilities		14,114	11,687	0	0	0	1,605	0	822	6,100	5,714	(385)
Corporate / other	Other medical equipment	514	514							210	194	(16)
	Nephrology / PICU scheme	260	260							16	6	(11)
	Glenfield Paddock repurchase	6,447	3,980				2,467			6,447	6,447	0
	Other Charity funded schemes	924				924				518	416	(102)
	LINAC	2,268	388		1,880					0	0	0
	Comet / Winter Pressures	71	71							0	0	0
	Air Conditioning	37	37							0	0	0
	Redrooms	141	141							0	0	0
	Nurses Education Infrastructure	50	50							0	0	0
	Microscopes – Histopathology	41	41							41	0	(41)
	Ultrasound Room - LRI	144	144							0	0	0
	Siemens Track system	220	220							0	0	0
	Vanguard scheme	846	0				846			0	0	0
	Decontamination mobile units	942	942				0			0	942	942
	Robotic Process Automation (RPA)	311	311			0				0	0	0
	Rapid cancer diagnostic pathways Genexus	300	0			300				0	0	0
	Digital OPG unit - DR Xray room	332	32			300				0	0	0
	Digital OPG unit - Imaging	32	8			24				0	0	0
	Community Diagnostic Hub (CDH)	2,631	0		2,631					0	149	149
	DREaM Academy	507	0		507					0	0	0
	Mediwell Cabinets	67	67							0	0	0
	EMIN	663	0		663					0	0	0
	Winter Headroom	350	350							0	0	0
Digital Pathology	3,400	0		3,400					0	0	0	
Endoscopy spend brought forward	600	600							0	0	0	
TIF schemes not included above	1,937	0		1,937					0	0	0	
Total Corporate / Other		24,035	8,156	0	11,642	924	3,313	0	0	7,232	8,153	921
Total Capital Programme		73,291	43,575	949	15,069	2,776	10,100	0	822	33,125	32,854	(271)
	Total STP spend	45,346	43,575	949					822			
	STP envelope	44,464										
	Available / (shortfall)	(883)										

Month 9 YTD capital expenditure was £32.8m against a YTD plan of £33.1m, representing an underspend against forecast of £0.3m. The total forecast is £73.3m, funded from a combination of internally generated funding (£43.6m); PDC (£16.0m); asset disposals (£10.1m); and Charitable Funds (£2.8m). During Month 9 we have included £2.7m of new schemes in the programme funded by the national Targeted Investment Fund PDC, all of which have been approved at CMIC and £1.5m is currently on order. Since the CMIC meeting on the 14th January 2022 we have updated the forecast for the Community Diagnostic Hub to reflect increased forecast spend of £0.4m. The capital sub group leads also confirmed at CMIC that they will deliver their capital programmes in line with the above forecast, although there remains a risk of deliverability given the commitments that must be achieved in the last quarter. NHSI and LLP ISC have been kept informed on a regular basis of forecast assumptions and risks, ensuring that assumptions are triangulated. A reworked forecast, reflecting assurances on capital works delivered and equipment delivered by 31 March 2022 is being undertaken w/c 23rd January, to validate the forecast.

The latest forecast assumes that we will be overspent by £0.9m overall. Although we previously received System approval to utilise £2.6m of LLP System level underspend in 2021/22 as funding for the Reconfiguration, additional PDC in 2022/23 cannot be drawn down to repay any system underspend that we use in the current year. As a result we have agreed with the LLP System finance team that we would not utilise any system underspend in the current year, beyond the £0.9m committed forecast overspend.